NexImmune (NEXI)
(Delayed Data from OTC)
$0.38 USD
0.00 (0.00%)
Updated Sep 12, 2024 12:29 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NEXI 0.38 0.00(0.00%)
Will NEXI be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NEXI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NEXI
What Makes NexImmune, Inc. (NEXI) a New Buy Stock
Biotech Stock Roundup: APLS, NVAX Gain on Updates, INCYs Regulatory News & More
NEXI: What are Zacks experts saying now?
Zacks Private Portfolio Services
NexImmune (NEXI) IND Gets Clearance for HPV-Related Cancer Drug
Other News for NEXI
NexImmune Dissolution Progresses with New Sole President
Buy Rating Affirmed for Nexi S.p.A. on Strong Fundamentals and Positive Financial Outlook
Nexi S.p.A. (NEXI) Receives a Buy from Kepler Capital
GLOBAL BROKER RATINGS: Barclays raises Ferrari; Goldman cuts lululemon
Nexi S.p.A. (NEXI) Receives a Buy from UBS